Mortality Risk of Fidelis Management⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Faddis, Mitchell N.
Journal of the American College of Cardiology Vol. 58, No. 3, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.011EDITORIAL COMMENT
Mortality Risk of
Fidelis Management*
Mitchell N. Faddis, MD, PHD
St. Louis, Missouri
The Fidelis lead recall is the latest in a series of device recalls
that have challenged clinicians with regard to appropriate
patient management strategies. Medtronic (Minneapolis,
Minnesota) recalled the Sprint Fidelis 6949 implantable
cardioverter-defibrillator (ICD) lead in 2007 after 665 lead
failures and 5 reported deaths. Prior to the recall, approxi-
mately 150,000 patients in the United States received the
Fidelis lead among about 268,000 patients worldwide. The
implications of these numbers for patient morbidity and
mortality that will result from device failure are sobering.
The challenge for physicians managing patients with func-
tioning Fidelis leads is to balance risks of prophylactic
replacement with or without extraction of the recalled lead
versus a conservative strategy of monitoring the lead’s
electrical performance in the hope that impending lead
failure will be predicted before a potentially lethal device
malfunction occurs. As a guide to this calculus, any data
about mortality risks of lead management strategies are
extremely helpful to clinicians. In this issue of the Journal,
the paper by Morrison et al. (1) provides this valuable
guidance.
See page 278
In the article, the authors retrospectively assay the impact
of a largely conservative management strategy for the Fidelis
lead employed at 3 prominent medical centers on all-cause
mortality in a cohort of patients who received the recalled
Fidelis lead relative to a cohort who received a non-recalled
Medtronic Quattro ICD lead manufactured contemporane-
ously. The 2 large cohorts were generated from 3 institu-
tions, totaling 1,030 in the Fidelis lead group and 1,621 in
the comparison group implanted with the Quattro lead. The
conservative management strategy observed in most patients
involved replacement of a malfunctioning Fidelis lead, with
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Department of Internal Medicine, Division of Cardiovascular Disease,
Washington University School of Medicine, St. Louis, Missouri. Dr. Faddis has
reported that he has no relationships to disclose.or without extraction, only when lead performance metrics
indicated a lead malfunction. Whether the downloadable
Lead Integrity Alert software, provided by Medtronic, was
used for the majority of patients was not stated but inferred
by the comment in the discussion that the lack of increased
mortality may have been due in part to the use of this
“downloadable algorithm.” The conservative management
strategy was followed in 94.9% of implanted Fidelis leads,
whereas prophylactic removal of a functioning Fidelis lead
was done in 5.1% of patients, of which 36% were
pacemaker-dependent patients as defined by 100% pacing.
Mortality was measured through a review of medical
records as well as the Social Security Death Index. Although
the absolute mortality was higher in the Fidelis cohort, the
difference was not significant after adjustment for relevant
comorbidities. Fidelis lead failures were identified in 85
patients from 1,030 implants, which corresponded to a
48-month lead survival of 87.0% compared with 98.7% of
the Quattro leads. None of these lead failures was associated
with death. In the Fidelis cohort, 155 patients were pace-
maker dependent, and 19 underwent prophylactic lead
replacement. Although there was not an increased mortality
risk in the pacemaker-dependent patients with the Fidelis
lead, 1 patient presented with asystole that required emer-
gency intervention. The authors did not attempt to adjudi-
cate the mechanism of deaths, so the possibility that some
fraction of the deaths were associated with a mechanism
involving lead failure could not be excluded.
How are we to incorporate this information into our own
practices for management of patients with the Fidelis lead?
As the authors so aptly state in the paper, “Management of
patients with implanted Fidelis leads involves balancing the
risk of malfunction, the ability of surveillance to detect
malfunction before catastrophic clinical events, and the risk
of intervention.” Most would agree that patients can be
divided into 2 groups for purposes of consideration of
prophylactic lead replacement, based upon the perceived
risk of a fatal complication resulting from a Fidelis lead
malfunction. In light of the data provided by Morrison et al.
(1), these 2 groups might be called a “low-risk” group and a
“lowest-risk” group. Patients in the lowest-risk group would
be those who received their device for primary prevention of
sudden death in the absence of pacing indications or serious
comorbidities. Patients in the other group who are predict-
ably at higher risk of a lethal complication resulting from
lead failure would be patients who are pacemaker dependent
or who received their device for secondary prevention of
sudden death. Armed with this patient triage scheme,
clinicians are guided by the Heart Rhythm Society Task
Force on Lead Performance Policies and Guidelines that
“lead revision or replacement should be considered if the
risk of malfunction is likely to lead to patient death or
serious harm, and the risk of revision or replacement is
believed to be less than the risk of patient harm from the
lead malfunction” (2). Of interest in light of this policy
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patients in the Fidelis cohort were managed with prophy-
lactic lead replacement.
One can infer from the low rate of prophylactic replace-
ment of functioning Fidelis leads observed in this report
that the perception among the group of participating
physicians was that the risk of morbidity or mortality
associated with replacement of the functioning lead, with or
without extraction, was high. Published data appear to
support that position. The report from the Canadian Heart
Rhythm Society Device Advisory Committee summarizing
the outcomes observed in a cohort of 469 patients referred
for revision or replacement of the Fidelis lead found a
complication rate of 19.8% of patients that underwent
extraction combined with lead replacement and 8.6% in
patients who had the Fidelis lead abandoned associated with
placement of a new lead (3). In this report summarizing the
outcomes from 25 Canadian Centers, 95% of patients with
Fidelis leads received a new ICD lead, with 53% of patients
undergoing an associated extraction. Four percent of pa-
tients received a new pace/sense lead only. Of the extrac-
tions, 61% of patients had the lead removed by traction,
33% of patients underwent laser lead extraction, and 1% of
patients with a nonpowered extraction tool. Fifty-one pa-
tients had failed traction extraction, with subsequent lead
abandonment. Two deaths were associated with lead revision,
with 1 patient dying from pneumonia post-operatively after
lead extraction, and the second patient dying from sepsis
related to an infected hematoma after lead abandonment.
An equally important consideration in the decision to
replace the Fidelis lead is patient-specific perceptions, not
only about risk of death and morbidity associated with
intervention, but also about the risk of inappropriate ICD
shocks resulting from Fidelis lead failure. In this report with
arguably ideal lead surveillance in place, 38 of the 85 lead
failures were associated with inappropriate shocks. This
observed rate was slightly higher than the observed rate in a
smaller cohort from a single facility described by Kallinen et
al. (4) where 4 in 23 patients with failed Fidelis leads
experienced inappropriate ICD shocks despite the Lead
Integrity Alert software algorithm. Most physicians who
follow patients with ICDs have encountered at least 1
patient who has experienced devastating anxiety that is long
lasting following a bout of inappropriate ICD shocks.
Avoidance of inappropriate ICD shocks will become an
increasingly important consideration in the decision toprophylactically replace the Fidelis lead as failure rates
increase.
The clinical decision making for management of patients
with the Fidelis leads continues to evolve as the lead failure
rate mounts. The study by Morrison et al. (1) provides an
important snapshot in time of the current mortality consid-
erations of a conservative strategy for managing these leads.
The conservative strategy appears justifiable at present
provided adequate intensive follow-up is available with
routine remote surveillance and implementation of the Lead
Integrity Alert software. The price to be paid for this
management strategy is inappropriate ICD shocks that
occur without warning of impending lead failure through
monitoring methods in a significant fraction of failing
Fidelis leads. The demonstration provided by Maytin et al.
(5) that lead extraction can be done with acceptably low
mortality and morbidity at high-volume centers suggests
that lead extraction can be considered for selected patients
when access to substantial clinical expertise with lead
extraction is available. For other centers, lead abandonment,
when possible, with placement of a new ICD lead may be
the preferred management strategy. ICD lead failure, even
among models with good reliability, remains a clinical man-
agement challenge with complex risk-benefit considerations.
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